Original Research

Published on 24 Jan 2024

The association and clinicopathological significance of Integrin alphavbeta6 and Rac1 expression in gastric carcinoma

in Cancer Molecular Targets and Therapeutics

Junjian Yu
Wenyu Jia
Qi Liu
Antai Yuan
Zhuoyu Jia
YuQi Sun
Zequn Li
Shougen Cao

Frontiers in Oncology

doi 10.3389/fonc.2024.1347270

993 views
1 citation

Case Report

Published on 24 Jan 2024

Treatment with palbociclib and tislelizumab for CDKN2A-mutated and PD-L1-positive advanced intrahepatic cholangiocarcinoma: a case report and literature review

in Cancer Molecular Targets and Therapeutics

Yajun Liang
Liya Hu
Huanlei Wu
Tiejun Yin
Jun Zhang

Frontiers in Oncology

doi 10.3389/fonc.2024.1292319

1,680 views
1 citation

Original Research

Published on 24 Jan 2024

IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors

in Cancer Molecular Targets and Therapeutics

Yu Wang
Shunsuke Shimosaki
Emi Ikebe
Hidekatsu Iha
Jun-ichi Yamamoto
Nichole Fife
Tomonaga Ichikawa
Mitsuo Hori
Masao Ogata
Yoshiyuki Tsukamoto

Frontiers in Oncology

doi 10.3389/fonc.2023.1272528

2,334 views
1 citation

Review

Published on 22 Jan 2024

Pediatric low-grade glioma models: advances and ongoing challenges

in Cancer Molecular Targets and Therapeutics

Griselda Metta Yvone
Joshua J. Breunig

Frontiers in Oncology

doi 10.3389/fonc.2023.1346949

2,576 views
5 citations

Case Report

Published on 22 Jan 2024

Deciphering the origin and therapeutic targets of cancer of unknown primary: a case report that illustrates the power of integrative whole-exome and transcriptome sequencing analysis

in Cancer Molecular Targets and Therapeutics

Majd Al Assaad
Nara Shin
Michael Sigouros
Jyothi Manohar
Zoia Antysheva
Nikita Kotlov
Daria Kiriy
Anastasiia Nikitina
Mikhail Kleimenov
Anastasiya Tsareva

Frontiers in Oncology

doi 10.3389/fonc.2023.1274163

1,830 views
1 citation

Editorial

Published on 19 Jan 2024

Editorial: Mechanisms of drug resistance to targeted therapy in malignancies

in Cancer Molecular Targets and Therapeutics

Masatsugu Hamaji

Frontiers in Oncology

doi 10.3389/fonc.2024.1363808

602 views

Original Research

Published on 18 Jan 2024

Depletion of the m1A writer TRMT6/TRMT61A reduces proliferation and resistance against cellular stress in bladder cancer

in Cancer Molecular Targets and Therapeutics

Ida Monshaugen
Luisa Luna
Jayden Rhodes
Felicia Iselin Svensson Kristiansen
Anna Lång
Stig Ove Bøe
Anindya Dutta
Zhangli Su
Arne Klungland
Rune Ougland

Frontiers in Oncology

doi 10.3389/fonc.2023.1334112

2,328 views
1 citation

Original Research

Published on 15 Jan 2024

Dual inhibition of atypical PKC signaling and PI3K/Akt signaling dysregulates c-Myc to induce apoptosis in clear cell Renal Cell Carcinoma

in Cancer Molecular Targets and Therapeutics

Khandker Mohammad Khalid
Wishrawana S. Ratnayake
Christopher A. Apostolatos
Mildred Acevedo-Duncan

Frontiers in Oncology

doi 10.3389/fonc.2023.1213715

1,647 views

Original Research

Published on 12 Jan 2024

Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer

in Cancer Molecular Targets and Therapeutics

Delfina Popiel
Aleksandra Stańczak
Monika Skupińska
Agata Mikołajczyk
Paulina Stańczak
Filip Mituła
Joanna Hucz-Kalitowska
Kinga Jastrzębska
Damian Smuga
Jakub Dominowski

Frontiers in Oncology

doi 10.3389/fonc.2023.1293728

2,104 views

Review

Published on 11 Jan 2024

Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity

in Cancer Molecular Targets and Therapeutics

Dennis Christoph Harrer
Florian Lüke
Tobias Pukrop
Lina Ghibelli
Christopher Gerner
Albrecht Reichle
Daniel Heudobler

Frontiers in Oncology

doi 10.3389/fonc.2023.1289222

2,614 views

Clinical Trial

Published on 10 Jan 2024

RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03)

in Cancer Molecular Targets and Therapeutics

Feng Wen
Tianhai Lin
Peng Zhang
Yali Shen

Frontiers in Oncology

doi 10.3389/fonc.2023.1233196

2,884 views
5 citations

Review

Published on 04 Jan 2024

The potential applications of artificially modified exosomes derived from mesenchymal stem cells in tumor therapy

in Cancer Molecular Targets and Therapeutics

Yilin Song
Quanlin Song
Daosheng Hu
Binwen Sun
Mingwei Gao
Xiangnan Liang
Boxin Qu
Lida Suo
Zeli Yin
Liming Wang

Frontiers in Oncology

doi 10.3389/fonc.2023.1299384

1,870 views
2 citations

Case Report

Published on 04 Jan 2024

Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma

in Cancer Molecular Targets and Therapeutics

Marwah Al-Aloosi
Amanda M. Prechtl
Payel Chatterjee
Brady Bernard
Christopher J. Kemp
Rachele Rosati
Robert L. Diaz
Lauren R. Appleyard
Shalini Pereira
Alex Rajewski

Frontiers in Oncology

doi 10.3389/fonc.2023.1267650

3,820 views
3 citations

Original Research

Published on 04 Jan 2024

Development of a cancer metastasis-on-chip assay for high throughput drug screening

in Cancer Molecular Targets and Therapeutics

Lutfiye Yildiz Ozer
Hend Salah Fayed
Johan Ericsson
Ayman Al Haj Zen

Frontiers in Oncology

doi 10.3389/fonc.2023.1269376

5,184 views
4 citations

Original Research

Published on 22 Dec 2023

MRI T2 mapping assessment of T2 relaxation time in desmoid tumors as a quantitative imaging biomarker of tumor response: preliminary results

in Cancer Molecular Targets and Therapeutics

Felipe F. Souza
Gina D’Amato
Emily Elizabeth Jonczak
Philippos Costa
Jonathan C. Trent
Andrew E. Rosenberg
Raphael Yechieli
H. Thomas Temple
Pradip Pattany
Ty K. Subhawong

Frontiers in Oncology

doi 10.3389/fonc.2023.1286807

1,700 views
1 citation

Review

Published on 22 Dec 2023

Desmoglein-2 as a cancer modulator: friend or foe?

in Cancer Molecular Targets and Therapeutics

Kay K. Myo Min
Charlie B. Ffrench
Barbara J. McClure
Michael Ortiz
Emma L. Dorward
Michael S. Samuel
Lisa M. Ebert
Mỹ G. Mahoney
Claudine S. Bonder

Frontiers in Oncology

doi 10.3389/fonc.2023.1327478

3,160 views

Navigation group

Articles

The association and clinicopathological significance of Integrin alphavbeta6 and Rac1 expression in gastric carcinoma

Treatment with palbociclib and tislelizumab for CDKN2A-mutated and PD-L1-positive advanced intrahepatic cholangiocarcinoma: a case report and literature review

IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors

Pediatric low-grade glioma models: advances and ongoing challenges

Deciphering the origin and therapeutic targets of cancer of unknown primary: a case report that illustrates the power of integrative whole-exome and transcriptome sequencing analysis

Editorial: Mechanisms of drug resistance to targeted therapy in malignancies

Depletion of the m1A writer TRMT6/TRMT61A reduces proliferation and resistance against cellular stress in bladder cancer

Dual inhibition of atypical PKC signaling and PI3K/Akt signaling dysregulates c-Myc to induce apoptosis in clear cell Renal Cell Carcinoma

Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer

Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity

RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03)

The potential applications of artificially modified exosomes derived from mesenchymal stem cells in tumor therapy

Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma

Development of a cancer metastasis-on-chip assay for high throughput drug screening

MRI T2 mapping assessment of T2 relaxation time in desmoid tumors as a quantitative imaging biomarker of tumor response: preliminary results

Desmoglein-2 as a cancer modulator: friend or foe?